Androgen deprivation therapy (ADT) is widely used in the treatment of metastatic, recurrent and locally advanced prostate cancer. However, ADT, which leads to castrate testosterone level, is associated with numerous side effects, such as sexual dysfunction, osteoporosis, obesity and cardiovascular morbidity. Once the serum testosterone level recovers to normal range, ADT-related side effects will disappear gradually. In this issue, Dai et al. (pages 466–470) found that in most clinically localized prostate cancer patients treated by surgery and subsequent short-term adjuvant ADT, serum testosterone can recover to normal range at 12 months after ADT cessation. Moreover, patients with higher baseline testosterone level need shorter time of testosterone normalization after ADT cessation. (Art by Xiang Chen)

这个话题很热，也算挺有意义。虽然杂志不高，但还是有前景。cover超级有爱~